No Data
No Data
NeuroSense Therapeutics Reports Phase 2b MicroRNA Data, Highlighting PrimeC's Promise As A Disease-Modifying ALS Treatment
Express News | Neurosense Therapeutics Announces Transformative Phase 2B Microrna Data, Highlighting Primec's Promise as a Disease-Modifying ALS Treatment
NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment
Express News | NeuroSense Therapeutics FY 2024 GAAP EPS $(0.54) Beats $(0.60) Estimate
6-K: Report of foreign private issuer (related to financial reporting)
Press Release: NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates